HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vettor, R. Articles by Federspil, G. Search for Related Content PubMed PubMed Citation Articles by Vettor, R. Articles by Federspil, G. Social Bookmarking                What's this?

Effect of Sibutramine on Weight Management and Metabolic Control in Type 2 Diabetes

A meta-analysis of clinical studies

From the Department of Medical and Surgical Sciences, Endocrine-Metabolic Laboratory, Internal Medicine, University of Padua, Padua, Italy

Address correspondence and reprint requests to Roberto Vettor, MD, Department of Medical and Surgical Sciences, University of Padova, via Ospedale, 105, 35128 Padova, Italy. E-mail: roberto.vettor{at}unipd.it

ABSTRACT

OBJECTIVE—The aim of this study was to provide a comprehensive meta-analysis of randomized controlled clinical studies on the effects of sibutramine on weight loss and glycemic control in obese subjects with type 2 diabetes.

RESEARCH DESIGN AND METHODS—Controlled clinical trials assessing the effect sizes of sibutramine on weight loss effects on glycemia in obese subjects with type 2 diabetes were identified and reviewed using the Cochrane Library, Medline, EMBASE, and a manual search.

RESULTS—Eight placebo-controlled, double-blind, randomized trials of sibutramine were included. After sibutramine treatment, the decrease in body weight and waist circumference was significantly greater than in the placebo group. Fasting blood glucose and HbA_1c significantly decreased after sibutramine treatment. Treatment benefits were seen in plasma triglycerides and HDL, without significant variations in serum total and LDL cholesterol. No differences in systolic blood pressure between the sibutramine and the placebo groups were seen, while recording of diastolic blood pressure and heart rate showed that sibutramine produced a small increase relative to placebo.

CONCLUSIONS—A pharmacological approach in a weight management program for patients with type 2 diabetes may be helpful in glycemic control and in the management of other risk factors. Sibutramine may help improve glucose control because it is conducive to weight loss. The reviewed data on the effect of sibutramine further enforce the recommendations that weight management may be the most important therapeutic task for most obese subjects with type 2 diabetes.

Abbreviations: DBP, diastolic blood pressure • SBP, systolic blood pressure

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Y.-Y. Lin, C.-W. Hsu, S.-J. Chu, and S.-H. Tsai Another dangerous combination for hypoglycemic coma: concurrent use of sibutramine and lorazepam QJM, March 1, 2008; 101(3): 243 - 245. [Full Text] [PDF]

				G. A. Bray and F. L. Greenway Pharmacological Treatment of the Overweight Patient Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184. [Full Text] [PDF]

				J. Rosenstock, P. Hollander, K. M. Gadde, X. Sun, R. Strauss, A. Leung, and for the OBD-202 Study Group A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Topiramate Controlled Release in the Treatment of Obese Type 2 Diabetic Patients Diabetes Care, June 1, 2007; 30(6): 1480 - 1486. [Abstract] [Full Text] [PDF]

				U. Pagotto, G. Marsicano, D. Cota, B. Lutz, and R. Pasquali The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance Endocr. Rev., February 1, 2006; 27(1): 73 - 100. [Abstract] [Full Text] [PDF]